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The anti-CD20 monoclonal antibody rituximab, together with
anthracycline, in hepatitis B surface antigen (HBsAg) healthy
carriers affected by non-Hodgkin lymphoma (NHL) increases
hepatitis B virus (HBV) reactivation risk.1 Oral primary antiviral
prophylaxis (PAVP) is a common strategy in this setting.2-4 Lam-
ivudine (LAM) has shown to be effective.5 HBsAg-seropositive pa-
tients undergoing R-CHOP-21 (IV cyclophosphamide [750 mg/m2],
doxorubicin [50 mg/m2], vincristine [1-4 mg/m2, maximum dose
2 mg], and rituximab [375 mg/m2] on day 1, and oral pred-
nisolone [100 mg] on days 1-5, administered every 21 days for
a total of 6 cycles)6,7 for diffuse large B-cell NHL (DLBCL)8 with
an adverse International Prognostic Index (IPI) score9 are at high
risk for antiviral prophylaxis failure.2-5 Tenofovir disoproxil fumarate
(TDF) is a new-generation oral nucleotide analog with stronger
antiviral activity and a higher genetic barrier to resistance than
LAM.2-5 We report a prospective series of HBsAg-seropositive
patients receiving TDF prophylaxis against HBV reactivation
concurrently with R-CHOP-21 chemotherapy as remission in-
duction for advanced-stage DLBCL.6,7 We then compared TDF
efﬁcacy and safety rates in these patients with those of a his-
torical cohort treated with LAM.
This study was conducted in the Hematology Unit of the
Federico II University. All necessary approvals were obtained
from our ethics committee. From February 2009 to June 2015,
consecutive HBsAg-seropositive patients with newly diagnosed
DLBCL scheduled to receive 6 cycles of R-CHOP-21 for adverse
prognostic factors9 received TDF (245 mg orally daily),3,4
whereas LAM (100 mg orally daily) was administered to a cohort
of patients with the same clinical characteristics from July 2004
to January 2009. The antiviral drug was begun 1 week before
chemotherapy and was scheduled to continue for 12 months
after the completion of chemotherapy.10,11 Liver function bio-
chemical tests and serum HBV DNA were monitored at
baseline and then every 1 to 3 months.10,11 At the indicated
time points, patients also underwent assessment of estimated
glomerular ﬁltration rate (eGFR) and bone mineral density.3,4
Efﬁcacy analysis focused primarily on HBV reactivation (HBV
DNA $ 2-log increase from baseline levels or new appearance
of HBV DNA $ 100 IU/mL) and secondarily on acute hepatitis
($3-fold increase in serum alanine aminotransferase level that
exceeded the reference range) and chemotherapy disruption
for HBV reactivation (premature termination of chemotherapy
or a delay $7 days between chemotherapy cycles).3,4 Safety
analysis focused on kidney and bone toxicity.
During the 6-year prospective study period, 39 patients received
TDF (TDF group). In the historical cohort, 38 patients received
LAM (LAM cohort). These 77 patients, who constituted the entire
population included in the ﬁnal assessment (Table 1), were in-
active HBsAg carriers with undetectable or low (n 5 26; median
320 IU/mL) serum HBV DNA levels at baseline. Thirty-two pa-
tients in the LAM cohort and 39 patients in the TDF group re-
ceived 6 cycles of R-CHOP-21, according to the standard
schedule. The median duration of PAVP treatment was
18 months with LAM (range, 4-18) and with TDF (range, 12-18).
Both antiviral prophylactic drugs were well tolerated with no
discontinuations as a result of adverse events, toxicity, or non-
compliance. Other supportive care measures (eg, pegﬁlgrastim,
antimicrobials) were given equally to the patients in both groups.
The median follow-up was 85.5 months in the LAM cohort vs
78 months in the TDF group. Emergent HBV DNA or exacer-
bation of HBV replication did not develop in any of the 39 pa-
tients in the TDF group compared with 15 of 38 patients in the
LAM cohort (median serum HBV DNA level, 3.5 3 106 IU/mL;
range, 1.4-7.0 3 106; absolute risk reduction, 0.395; 95% con-
ﬁdence interval [CI], 0.229-0.553; P , .0001). Six reactivations
appeared in patients with detectable serum HBV DNA (median,
200 IU/mL; range, 100-948) at pretreatment. The median time
to HBV reactivation after immune-chemotherapy initiation was
6 months (range, 4-36), with 4 reactivations beyond 12 months.
None of the patients in the TDF group developed acute hepatitis
compared with 4 patients (with massive HBV replication) in the
LAM cohort. Thus, the rate of HBV-related acute hepatitis was
lower for the TDF group vs the LAM cohort (absolute risk re-
duction, 0.105; 95%CI,20.005 to 0.241; P5 .054). No patient in
the TDF group and 6 patients in the LAM cohort experienced
chemotherapy disruption for early HBV reactivation and/or HBV-
related hepatitis (absolute risk reduction, 0.158, 95% CI, 0.035-
0.304; P5 .012). In the LAM cohort, themean baseline eGFRwas
95.36 19.0mL/min per 1.73m2, and this was 88.66 21.0mL/min
per 1.73 m2 (a reduction of 7%) at the end of the study. In the TDF
group, the mean baseline eGFR was 94.3 6 18.0 mL/min per
1.74 m2 and 87.6 6 20.0 mL/min per 1.74 m2 at the end of the
study (a reduction of 7.2%). Dual energy x-ray absorptiometry
scanning from baseline to the end of the study revealed osteo-
penia in ;10% of the patients in each group. Three-year
progression-free survival was 75.4% in the LAM cohort and
76.3% in the TDF group, and 3-year overall survival was
63.8% and 65.7%, respectively.
The Bay of Naples is considered endemic for chronic HBV
infection10,11; thus, it is not uncommon that a candidate to an-
tineoplastic treatment of lymphoma is an inactive HBsAg carrier.
In real life, patients with chronic HBV infection and aggressive
lymphomas8 are at higher risk for antiviral prophylaxis failure,
with virus breakthrough likely due to poorer performance status
and deeper immunosuppression.2-5 In this era-to-era comparing
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trial, we analyzed the largest (n5 39 cases) and longest (median
follow-up, 6.5 years) prospective series of HBsAg-seropositive
patients treated with TDF vs a historic cohort treated with LAM
against HBV reactivation following lengthy immune-chemotherapy.6,7
Of note is the particular homogeneity of the study population in
terms of underlying malignant disease (stages III-IV DLBCLs),8
front-line antineoplastic treatment (R-CHOP-21 scheduled for
6 cycles),6,7 and duration of PAVP (12 months).3,4 The risk of HBV
reactivation (primary end point) in patients protected with TDF
was ;40 percentage points lower (HBV-related acute hepatitis
and chemotherapy disruption, 10 and 15 percentage points lower,
respectively) compared with LAM, indicating that TDF is clini-
cally very effective.12 Until now, there are no relevant data on the
use of oral nucleos(t)ide analogs with a high genetic barrier to
resistance in this setting.3,4 By systematically reviewing the lit-
erature, we found 5 articles on entecavir vs LAM and 3 articles
on TDF vs LAM as prophylactic treatment for chronic HBV
infection–related complications in a total of 170 HBsAg1 par-
ticipants scheduled to undergo 6 cycles of R-CHOP-21 induction
therapy for B-cell NHL.13-19 The HBV-related outcomes are re-
ported in Table 2. The median reactivation rates, acute hep-
atitis, and chemotherapy disruption among the patients in the
entecavir arms were 10% (range, 0-12%), 4% (range, 0-6%), and
2% (range, 0-6%), respectively, vs 0%, 0%, and 0% (with ranges
of 0-0%), respectively, among the patients in the TDF arms.
Thus, TDF had the highest probability (100%) for HBV reac-
tivation and HBV-related acute hepatitis and chemotherapy
disruption rate reduction in this cohort of lymphoma patients.9
Oncologists and hepatologists/infectious disease specialists,
who coordinate the management of HBV infection, should be
aware of cost-effectiveness. Using Italian data, the total cost of
the TDF program was €277 149 compared with €40 424 for the
LAM cohort. However, if the additional costs of reactivations,
acute hepatitis, and retreatment with a new antiviral drug in
the LAM cohort are considered, the cost of the TDF approach
was ;1.69-fold higher than treatment with LAM. Altogether,
these data suggest that the TDF-driven strategy may be
more effective than a LAM-driven strategy in the prevention
of HBV reactivation and its related morbidity for patients
with chronic HBV infection undergoing repeated courses of
immune-chemotherapy for B-cell lymphomas.6,7 Larger studies
are needed to demonstrate a survival advantage from PAVP
with TDF in patients with advanced-stage DLBCL20 and adverse
IPI scores.9
Table 1. Baseline characteristics of analyzed patients
Variables TDF (n 5 39) LAM (n 5 38) P
Age, median (range), y 59.5 (25-81) 61 (21-83) .64
Sex
Male 23 (59) 21 (55.3) .74
Female 16 (41) 17 (44.7)
Underlying hematological malignancy (DLBCL) 39 (100) 38 (100) n.v.
Ann Arbor stage*
Stage III 20 (51.3) 18 (47.4) .73
Stage IV 19 (48.7) 20 (52.6)
IPI score†
1 2 (5.1) 1 (2.6) .57
2-3 15 (38.5) 15 (39.5) .92
4-5 22 (56.4) 22 (57.9) .89
HBV status in the serum at pretreatment
HBsAg1 39 (100) 38 (100) n.v.
HBcAb1 32 (82.1) 34 (89.5) .35
HBV DNA‡ at pretreatment
HBV DNA1 12 (30.7) 14 (36.8) .57
Median (range), IU/mL 499 (100-948) 483 (100-1800) .58
Transaminase level
AST #40 IU/L 39 (100) 38 (100) n.v.
ALT #40 IU/L 39 (100) 38 (100) n.v.
Scheduled induction immune-chemotherapy
(R-CHOP-21)
39 (100) 38 (100) n.v.
Unless otherwise indicated, data are n (%). No patient had hepatitis C or delta or HIV coinfections.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBcAb, hepatitis B core antibody; n.v., not valuable; TDF, tenofovir disoproxil fumarate.
*Stage III is deﬁned as multiple lymph node groups on both sides of the diaphragm; stage IV is deﬁned as multiple extranodal sites or lymph nodes and extranodal disease.20
†Five factors were included: age . 60 years, serum lactate dehydrogenase above normal, Eastern Cooperative Oncology Group performance status of 2 to 4, Ann Arbor stage III or IV, and
extranodal involvement at .1 site. Each factor gets 1 point, and possible scores range from 0 to 5. A higher score indicates poorer prognosis.9
‡By real-time PCR (cutoff 5 20 IU/mL).
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